LIBERO VISIBLE
Prospective, observational, non-interventionaL, multicenter real-world evIdence (RWE) study of Brodalumab 210 mg (Kyntheum®) to manage patients with modERate-to-severe plaque psOriasis with stigmatizing or VISIBLE lesions in daily practice (LIBERO VISIBLE)